Insmed, Inc. (INSM)
124.03
-1.74
(-1.38%)
USD |
NASDAQ |
Aug 24, 16:00
124.03
0.00 (0.00%)
After-Hours: 20:00
Insmed Enterprise Value : 27.04B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 27.04B |
| August 20, 2026 | 26.89B |
| August 19, 2026 | 28.11B |
| August 18, 2026 | 27.63B |
| August 17, 2026 | 27.60B |
| August 14, 2026 | 26.60B |
| August 13, 2026 | 27.16B |
| August 12, 2026 | 28.46B |
| August 11, 2026 | 28.52B |
| August 10, 2026 | 29.00B |
| August 07, 2026 | 28.20B |
| August 06, 2026 | 28.52B |
| August 05, 2026 | 21.20B |
| August 04, 2026 | 21.14B |
| August 03, 2026 | 21.08B |
| July 31, 2026 | 21.11B |
| July 30, 2026 | 21.74B |
| July 29, 2026 | 22.10B |
| July 28, 2026 | 22.32B |
| July 27, 2026 | 22.45B |
| July 24, 2026 | 22.93B |
| July 23, 2026 | 23.03B |
| July 22, 2026 | 22.86B |
| July 21, 2026 | 23.30B |
| July 20, 2026 | 22.95B |
| Date | Value |
|---|---|
| July 17, 2026 | 23.23B |
| July 16, 2026 | 23.04B |
| July 15, 2026 | 23.56B |
| July 14, 2026 | 23.62B |
| July 13, 2026 | 23.41B |
| July 10, 2026 | 24.82B |
| July 09, 2026 | 25.40B |
| July 08, 2026 | 25.02B |
| July 07, 2026 | 24.22B |
| July 06, 2026 | 23.93B |
| July 02, 2026 | 23.95B |
| July 01, 2026 | 22.94B |
| June 30, 2026 | 22.86B |
| June 29, 2026 | 22.20B |
| June 26, 2026 | 21.91B |
| June 25, 2026 | 22.14B |
| June 24, 2026 | 21.93B |
| June 23, 2026 | 21.64B |
| June 22, 2026 | 20.88B |
| June 18, 2026 | 20.27B |
| June 17, 2026 | 20.84B |
| June 16, 2026 | 20.21B |
| June 15, 2026 | 20.63B |
| June 12, 2026 | 20.71B |
| June 11, 2026 | 20.47B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 31.27B |
| United Therapeutics Corp. | 19.24B |
| ACADIA Pharmaceuticals, Inc. | 4.195B |
| Biogen, Inc. | 39.09B |
| Gilead Sciences, Inc. | 202.61B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.24M |
| Revenue (Quarterly) | 425.49M |
| Total Expenses (Quarterly) | 438.73M |
| EPS Diluted (Quarterly) | -0.0609 |
| Gross Profit Margin (Quarterly) | 83.71% |
| Profit Margin (Quarterly) | -3.11% |
| Earnings Yield | -3.31% |
| Normalized Earnings Yield | -3.228 |